Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine

Drug Delivery

Volumn 21, Issue 8, 2014, Pages 627-635

  Singh, Gurinder ^a   Pai, Roopa S ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Central composite design; Controlled release; in vivo biodistribution; Nanoparticles; Pharmacokinetic study

Indexed keywords

EMTRICITABINE; NANOPARTICLE; POLYGLACTIN; ANTIVIRUS AGENT; DELAYED RELEASE FORMULATION; DEOXYCYTIDINE; EXCIPIENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BRAIN; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG STABILITY; DRUG TISSUE LEVEL; HALF LIFE TIME; HEART; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LIVER; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; RAT; REDUCTION; RETICULOENDOTHELIAL SYSTEM; SPLEEN; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; DELAYED RELEASE FORMULATION; MEDICINAL CHEMISTRY; REPRODUCIBILITY; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; LACTIC ACID; MALE; NANOPARTICLES; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION;

EID: 84913616296     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.867382     Document Type: Article

References (34)

1. Alhareth K, Vauthier C, Bourasset F, et al. (2012). Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles. Eur J Pharm Biophar 81: 453-7.
2. Bala I, Hariharan S, Kumar MNVR. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carr Syst 21: 387-422.
3. Beloqui A, Solinis MA, Gascon AR, et al. (2013). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Contr Release 166: 115-23.
4. Bender AR, Briesen HV, Kreuter J, et al. (1996). Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 4: 1467-71.
5. Bhardwaj V, Hariharan S, Bala S, et al. (2005). Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotechnol 1: 235-58.
6. ® L100 and Eudragit L100-PLGA nanoparticles containing diclofenac sodium. AAPS Pharm Sci Tech 11: 1250-6.
7. Dabrowska MM. (2011). Once-daily single tablet regimen of tenofovir/emtricitabine/efavirenz-Potent, safe and convenient approach to combined antiretroviral therapy. HIV & AIDS Rev 10: 38-9.
8. Devi KV, Pai RS. (2006). Antiretrovirals: need for an effective drug delivery. Indian J Pharm Sci 68: 1-6.
9. Dillen K, Vandervoort J, Van den G, et al. (2006). Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 314: 72-82.
10. Dodiya SS, Chavhan SS, Sawant KK, et al. (2011). Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J Microencapsul 28: 515-27.
11. Feng S, Huang G. (2001). Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release 71: 53-69.
12. Fonseca C, Simoes S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Rel 83: 273-86.
13. Hamarapurkar PD, Parate AN. (2013). HPLC method for the determination of emtricitabine and related degradation substances. J Chromatogr Sci 51: 419-24.
14. Hariharan S, Bhardwaj V, et al. (2006). Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res 23: 184-95.
15. Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21: 2475-90.
16. Kumar G, Malhotra S, Shafiq N, et al. (2011). In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J Microencapsul 28: 717-28.
17. Kumari A, Yadav SK, Yadav SC. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75: 1-18.
18. Lai SK, Wang YY, Hanes J. (2009). Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61: 158-71.
19. Lamorde M, Kibwika PB, Tamale WS, et al. (2012). Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in ugandan adults. AIDS Res Treat. Article ID 105980, 6 pages, doi: 10.1155/2012/105980.
20. Mathot F, Beijsterveldt L, Preat V, et al. (2006). Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Controlled Release 111: 47-55.
21. Milani PZ, Loveymi BD, Jelvehgari M, et al. (2013). The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 103: 174-81.
22. Mittal G, Sahana DK, Bhardwaj V, et al. (2007). Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Contr Release 119: 77-85.
23. Nirogi R, Bhyrapuneni G, Kandikere V, et al. (2012). Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats. Biopharm Drug Dispos 33: 265-77.
24. Olin JL, Spooner LM, Klibanov OM. (2012). Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for hiv-1 infection treatment. Ann Pharmacother 46: 671-7.
25. Parikh UM, Dobard C, Sharma S, et al. (2009). Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 83: 10358-65.
26. Q1A(R2). (2003). Stability testing of new drug substances and products.
27. Singh B, Kapil R, Nandi M, et al. (2011). Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv 8: 1341-60.
28. Singh G, Pai RS, Devi VK. (2012a). Response surface methodology and process optimization of sustained release pellets using Taguchi orthogonal array design and central composite design. J Adv Pharm Tech Res 3: 30-40.
29. Singh G, Pai RS, Devi VK. (2012b). Optimization of pellets containing solid dispersion prepared by extrusion/spheronization using central composite design and desirability function. J Young Pharmacists 4: 146-56.
30. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J Contr Release 70: 1-20.
31. Su Y, Lee SH, Sinko PJ. (2004). Practical aspects of transporter model systems: A case study involving SQV. Drug Metab Rev 36: 377-89.
32. Wang LH, Wiznia AA, Rathore MH, et al. (2004). Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 48: 183-91.
33. United States Pharmacopeia. (2011). USP, USP 34, NF 29, The United States Pharmacopeia and The National Formulary. Rockwille, MD: The United States Pharmacopeial Convention; 20852.
34. Zhao P, Wang H, Yu M, et al. (2012). Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: In vitro and in vivo evaluation. Eur J Pharm Biopharm 81: 248-56.